native and recomb. COX-1, no cross reaction with COX-2
No Available References
- The EMA Deems Brain Atrophy Valid Trial Selection Measure
- Paris: Standardization a Hurdle for Spinal Fluid, Imaging Markers
- San Diego: Pre-AD Brain Changes May Allow Early Diagnosis
- Experimental α7 Agonist Meets Cognitive and Clinical Endpoints
- New Assays for Aβ Oligomers in CSF Claim Femtogram Sensitivity
- Q&A With Roche’s CNS Leader Luca Santarelli
- When Is a C9ORF72 Repeat Expansion Not a C9ORF72 Repeat Expansion?
- Wave of New BACE Inhibitors Heading to Phase 2
- Researchers Join to Draw Posterior Cortical Atrophy Out of Shadows
- CSF Markers: Goodbye, Research Use Only; Hello, Clinical
- Metrology, Certification Heavies Take CSF Tests Under Their Wings
- Cochrane Asks for Field’s Input on Draft Reporting Standards
- Aβ’s Good Side—Can It Improve Symptoms of Multiple Sclerosis?